605 related articles for article (PubMed ID: 32816843)
41. D-1553: A novel KRAS
Shi Z; Weng J; Niu H; Yang H; Liu R; Weng Y; Zhu Q; Zhang Y; Tao L; Wang Z; Huh SJ; Jiang Y; Mei H; Dai X; Zhang L; Wang Y
Cancer Sci; 2023 Jul; 114(7):2951-2960. PubMed ID: 37158138
[TBL] [Abstract][Full Text] [Related]
42. The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
Sudhakar N; Yan L; Qiryaqos F; Engstrom LD; Laguer J; Calinisan A; Hebbert A; Waters L; Moya K; Bowcut V; Vegar L; Ketcham JM; Ivetac A; Smith CR; Lawson JD; Rahbaek L; Clarine J; Nguyen N; Saechao B; Parker C; Elliott AJ; Vanderpool D; He L; Hover LD; Fernandez-Banet J; Coma S; Pachter JA; Hallin J; Marx MA; Briere DM; Christensen JG; Olson P; Haling J; Khare S
Mol Cancer Ther; 2024 Apr; ():. PubMed ID: 38641404
[TBL] [Abstract][Full Text] [Related]
43. Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models.
Del Curatolo A; Conciatori F; Cesta Incani U; Bazzichetto C; Falcone I; Corbo V; D'Agosto S; Eramo A; Sette G; Sperduti I; De Luca T; Marabese M; Shirasawa S; De Maria R; Scarpa A; Broggini M; Del Bufalo D; Cognetti F; Milella M; Ciuffreda L
J Exp Clin Cancer Res; 2018 Jul; 37(1):140. PubMed ID: 29986755
[TBL] [Abstract][Full Text] [Related]
44. Design of Orally-bioavailable Tetra-cyclic phthalazine SOS1 inhibitors with high selectivity against EGFR.
He H; Chen R; Wang Z; Qing L; Zhang Y; Liu Y; Pan W; Fang H; Zhang S
Bioorg Chem; 2023 Jul; 136():106536. PubMed ID: 37054529
[TBL] [Abstract][Full Text] [Related]
45. Discovery of the First-in-Class Agonist-Based SOS1 PROTACs Effective in Human Cancer Cells Harboring Various KRAS Mutations.
Zhou C; Fan Z; Zhou Z; Li Y; Cui R; Liu C; Zhou G; Diao X; Jiang H; Zheng M; Zhang S; Xu T
J Med Chem; 2022 Mar; 65(5):3923-3942. PubMed ID: 35230841
[TBL] [Abstract][Full Text] [Related]
46. MEK and TAK1 Regulate Apoptosis in Colon Cancer Cells with KRAS-Dependent Activation of Proinflammatory Signaling.
McNew KL; Whipple WJ; Mehta AK; Grant TJ; Ray L; Kenny C; Singh A
Mol Cancer Res; 2016 Dec; 14(12):1204-1216. PubMed ID: 27655129
[TBL] [Abstract][Full Text] [Related]
47. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
48. SHP2 inhibitor specifically suppresses the stemness of KRAS-mutant non-small cell lung cancer cells.
Jiang L; Xu W; Chen Y; Zhang Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):3231-3238. PubMed ID: 31373232
[TBL] [Abstract][Full Text] [Related]
49. Overcoming Resistance to Dual Innate Immune and MEK Inhibition Downstream of KRAS.
Kitajima S; Asahina H; Chen T; Guo S; Quiceno LG; Cavanaugh JD; Merlino AA; Tange S; Terai H; Kim JW; Wang X; Zhou S; Xu M; Wang S; Zhu Z; Thai TC; Takahashi C; Wang Y; Neve R; Stinson S; Tamayo P; Watanabe H; Kirschmeier PT; Wong KK; Barbie DA
Cancer Cell; 2018 Sep; 34(3):439-452.e6. PubMed ID: 30205046
[TBL] [Abstract][Full Text] [Related]
50. Discovery of KRB-456, a KRAS G12D Switch-I/II Allosteric Pocket Binder That Inhibits the Growth of Pancreatic Cancer Patient-derived Tumors.
Kazi A; Ranjan A; Kumar M V V; Agianian B; Garcia Chavez M; Vudatha V; Wang R; Vangipurapu R; Chen L; Kennedy P; Subramanian K; Quirke JCK; Beato F; Underwood PW; Fleming JB; Trevino J; Hergenrother PJ; Gavathiotis E; Sebti SM
Cancer Res Commun; 2023 Dec; 3(12):2623-2639. PubMed ID: 38051103
[TBL] [Abstract][Full Text] [Related]
51. ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
Peng DH; Kundu ST; Fradette JJ; Diao L; Tong P; Byers LA; Wang J; Canales JR; Villalobos PA; Mino B; Yang Y; Minelli R; Peoples MD; Bristow CA; Heffernan TP; Carugo A; Wistuba II; Gibbons DL
Sci Transl Med; 2019 Mar; 11(483):. PubMed ID: 30867319
[TBL] [Abstract][Full Text] [Related]
52. Design and Structural Optimization of Orally Bioavailable SOS1 Inhibitors for the Treatment of KRAS-Driven Carcinoma.
Zhang S; Zhang Y; Chen X; Xu J; Fang H; Li Y; Liu Y; He H
J Med Chem; 2022 Dec; 65(23):15856-15877. PubMed ID: 36384290
[TBL] [Abstract][Full Text] [Related]
53. The HSP90 inhibitor, NVP-AUY922, attenuates intrinsic PI3K inhibitor resistance in KRAS-mutant non-small cell lung cancer.
Park KS; Yang H; Choi J; Seo S; Kim D; Lee CH; Jeon H; Kim SW; Lee DH
Cancer Lett; 2017 Oct; 406():47-53. PubMed ID: 28797845
[TBL] [Abstract][Full Text] [Related]
54. Targeting the MAPK Pathway in KRAS-Driven Tumors.
Drosten M; Barbacid M
Cancer Cell; 2020 Apr; 37(4):543-550. PubMed ID: 32289276
[TBL] [Abstract][Full Text] [Related]
55. Relationships among
Wan XB; Wang AQ; Cao J; Dong ZC; Li N; Yang S; Sun MM; Li Z; Luo SX
World J Gastroenterol; 2019 Feb; 25(7):808-823. PubMed ID: 30809081
[TBL] [Abstract][Full Text] [Related]
56. Discovery of Orally Bioavailable SOS1 Inhibitors for Suppressing KRAS-Driven Carcinoma.
He H; Zhang Y; Xu J; Li Y; Fang H; Liu Y; Zhang S
J Med Chem; 2022 Oct; 65(19):13158-13171. PubMed ID: 36173339
[TBL] [Abstract][Full Text] [Related]
57. Targeting Son of Sevenless 1: The pacemaker of KRAS.
Kessler D; Gerlach D; Kraut N; McConnell DB
Curr Opin Chem Biol; 2021 Jun; 62():109-118. PubMed ID: 33848766
[TBL] [Abstract][Full Text] [Related]
58. Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify
Talwelkar SS; Nagaraj AS; Devlin JR; Hemmes A; Potdar S; Kiss EA; Saharinen P; Salmenkivi K; Mäyränpää MI; Wennerberg K; Verschuren EW
Mol Cancer Ther; 2019 Oct; 18(10):1863-1874. PubMed ID: 31320402
[TBL] [Abstract][Full Text] [Related]
59. KRAS
Zhou ZW; Ambrogio C; Bera AK; Li Q; Li XX; Li L; Son J; Gondi S; Li J; Campbell E; Jin H; Okoro JJ; Xu CX; Janne PA; Westover KD
Cancer Res; 2020 Sep; 80(17):3719-3731. PubMed ID: 32605999
[TBL] [Abstract][Full Text] [Related]
60. Unique dependence on Sos1 in
You X; Kong G; Ranheim EA; Yang D; Zhou Y; Zhang J
Blood; 2018 Dec; 132(24):2575-2579. PubMed ID: 30377195
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]